A Critical Review of Tacrolimus for Psoriasis: Mechanisms, Efficacy, and Clinical Outcomes

Tacrolimus, a calcineurin inhibitor used in atopic dermatitis as a therapeutic option in psoriasis. The literature reviewed from 2020 to 2024 indicates that topical tacrolimus is effective for the treatment of mild-to-moderate psoriasis with a good safety profile. This drug mechanism involves the inhibition of T-cell activation which is believed to be very important in the disease process of psoriasis. Clinical trials and observational studies have evidenced marked improvements in the PASI scores, combined with reduced erythema, scaling and induration. Besides tacrolimus is well-tolerated with very minimal systemic absorption and fewer adverse effects compared to traditional therapies. However, its efficacy in plaque psoriasis may be limited because of the vehicle of the drug which can provide a barrier to penetration in thickened lesions. Studies on formulation, optimization and combination regimens continue to enhance efficacy. In general tacrolimus offers a very useful therapeutic modality in the management of psoriasis of sensitive skin sites. Overall, this is an alternative to corticosteroids with fewer side effects and showing comparable efficacy.